These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 9809686)

  • 41. PSA and the family physician.
    Barkin J
    Can J Urol; 2011 Apr; 18 Suppl():20-3. PubMed ID: 21501547
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer.
    Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
    Int J Cancer; 2004 Apr; 109(3):455-60. PubMed ID: 14961587
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The influence of physician recommendation on prostate-specific antigen screening.
    Pucheril D; Dalela D; Sammon J; Sood A; Sun M; Trinh QD; Menon M; Abdollah F
    Urol Oncol; 2015 Oct; 33(10):424.e1-7. PubMed ID: 26206103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Informed consent for prostate-specific antigen screening.
    Catalona WJ
    Urology; 2003 Jan; 61(1):17-9. PubMed ID: 12559258
    [No Abstract]   [Full Text] [Related]  

  • 45. Early detection of prostate cancer. Role of prostate-specific antigen.
    Prabhakaran VM
    Can Fam Physician; 1996 Apr; 42():709-12. PubMed ID: 8653039
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
    Howard K; Barratt A; Mann GJ; Patel MI
    Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Informed consent for prostate-specific antigen screening.
    Wilkinson S; Chodak G
    Urology; 2003 Jan; 61(1):2-4. PubMed ID: 12559252
    [No Abstract]   [Full Text] [Related]  

  • 48. Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark.
    Jønler M; Eddy B; Poulsen J
    Scand J Urol Nephrol; 2005; 39(3):214-8. PubMed ID: 16118092
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Informed consent for prostate-specific antigen-based screening.
    Brawley OW
    Urology; 2003 Jan; 61(1):10-2. PubMed ID: 12559255
    [No Abstract]   [Full Text] [Related]  

  • 50. PSA testing: are patients aware of what lies ahead?
    Lamplugh M; Gilmore P; Quinlan T; Cornford P
    Ann R Coll Surg Engl; 2006 May; 88(3):284-8. PubMed ID: 16720000
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.
    Zanwar P; Lin YL; Kuo YF; Goodwin JS
    BMC Health Serv Res; 2016 Jan; 16():17. PubMed ID: 26772175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prostate-specific antigen testing of older men.
    Carter HB; Landis PK; Metter EJ; Fleisher LA; Pearson JD
    J Natl Cancer Inst; 1999 Oct; 91(20):1733-7. PubMed ID: 10528023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostate-specific antigen levels in 1695 men without evidence of prostate cancer. Findings of the American Cancer Society National Prostate Cancer Detection Project.
    Kane RA; Littrup PJ; Babaian R; Drago JR; Lee F; Chesley A; Murphy GP; Mettlin C
    Cancer; 1992 Mar; 69(5):1201-7. PubMed ID: 1371234
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An evaluation of usefulness of prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer in an unscreened population:experience in a Nigerian teaching hospital.
    Ojewola RW; Tijani KH; Jeje EA; Ogunjimi MA; Anunobi CC; Adesanya AO
    West Afr J Med; 2013; 32(1):8-13. PubMed ID: 23613288
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brief report: physicians and their personal prostate cancer-screening practices with prostate-specific antigen. A national survey.
    Chan EC; Barry MJ; Vernon SW; Ahn C
    J Gen Intern Med; 2006 Mar; 21(3):257-9. PubMed ID: 16637825
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Informed consent for prostate-specific antigen testing.
    Gann PH
    Urology; 2003 Jan; 61(1):5-6. PubMed ID: 12559253
    [No Abstract]   [Full Text] [Related]  

  • 58. Unravelling the prostate-specific antigen controversy: a West of Scotland perspective.
    Zafar N; Miller S; Leburn V; Qureshi KN; Rajan P
    Scott Med J; 2014 May; 59(2):126-9. PubMed ID: 24682103
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence of effectiveness.
    Burack RC; Wood DP
    Med Clin North Am; 1999 Nov; 83(6):1423-42, vi. PubMed ID: 10584601
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
    Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
    BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.